NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES.
 
Reference is made to NorDiag ASA's ("NorDiag" or the "Company") stock exchange announcements on 2 April and 20 April 2012 regarding the potential asset sale by the Company.

Enclosed are the minutes from the Extraordinary General Meeting in NorDiag held today, 23 April 2012. 129,888,701 of a total of 279,880,720 shares and votes were represented at the General Meeting, or approximately 46.4% of the share capital. All resolutions were made in accordance with the Board of Directors' proposals.

For further information, please contact:
CEO Mårten Wigstøl,  Phone: +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.

 
Minutes from EGF

Read the notice in Norwegian here.